Aggression in huntington's disease: A systematic review of rates of aggression and treatment methods

Journal of Huntington's Disease

Volumn 3, Issue 4, 2014, Pages 319-332

  Fisher, Caroline A ^a,b   Sewell, Katherine ^b   Brown, Anahita ^b   Churchyard, Andrew ^c,d  

^a BOX HILL HOSPITAL   (Australia)

^b AUSTIN HEALTH   (Australia)

^c Huntington's Disease Service Calvary Health Care Bethlehem   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Aggression; Huntington's disease; prevalence; therapy; treatment

Indexed keywords

PSYCHOTROPIC AGENT;

AGGRESSION; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR DISORDER; FUNCTIONAL STATUS; HOSPITAL PERSONNEL; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; MINI MENTAL STATE EXAMINATION; OBSESSIVE COMPULSIVE DISORDER; SEX DIFFERENCE; SUICIDAL IDEATION; SYSTEMATIC REVIEW; THERAPY EFFECT; UNIFIED HUNTINGTON DISEASE RATING SCALE; VERBAL BEHAVIOR; VERBAL HOSTILITY; FEMALE; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PATHOLOGY; PREVALENCE; PSYCHOLOGY;

AGGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PREVALENCE; PSYCHOTROPIC DRUGS;

EID: 84928695807     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140127     Document Type: Article

References (55)

1. Gusella G, Wexler N, Conneally P, Naylor S, Anderson M, Tanzi R, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature. 1983;306:234-38.
2. Group THDCR. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-83.
3. Walker F. Huntington's disease. Lancet. 2007;369(9557):218-28.
4. Brandt J, Butters N. The neuropsychology of Huntington's disease. Trends Neurosci. 1986;9:118-20.
5. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation. J Neurol. 2004;251(8):935-42.
6. Paulsen J, Ready R, Hamilton J, Mega M, Cummings J. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310-4.
7. Dewhurst K, Oliver J, McKnight A. Socio-Psychiatric Consequences of Huntington's Disease. Br J Psychiatry. 1970;116(532):255-8.
8. Wheelock V, Tempkin T, Marder K, Nance M, Myers R, Zhao H, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60(6):998-1001.
9. Rosenblatt A, Leroi I. Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics. 2000;41(1):24-30.
10. Cummings J. Behavioral and psychiatric symptoms associated with Huntington's disease. Adv Neurol. 1995;65:179-86.
11. Folstein S, Folstein M. Psychiatric features of Huntington's disease: Recent approaches and findings. Psychiatr Dev. 1983;1(2):193-205.
12. Bushman B, Anderson C. Methodology in the Study of Aggression: Integrating Experimental and Nonexperimental Findings. In: Geen, RG, Donnerstein E, editor. Human Aggression: Theories, Research, and Implications for Social Policy. San Diego: Academic Press; 1998. pp. 23-48.
13. Groves M, van Duijn E, Anderson K, Craufurd D, Edmondson MC, Goodman N, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr. 2011;3.
14. Reedeker N, Bouwens JA, Giltay EJ, Le Mair SE, Roos RAC, van der Mast RC, et al. Irritability in Huntington's disease. Psychiatry Res. 2012;200(2-3):813-8.
15. Van Duijn E, Craufurd D, Hubers A, Giltay E, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411-8.
16. Snaith RP, Taylor CM. Irritability: Definition, assessment and associated factors. Br J Psychiatry. 1985;147(2):127-36.
17. Holtzman S, O'Connor BP, Barata PC, Stewart DE. The Brief Irritability Test (BITe) A Measure of Irritability for Use Among Men and Women. Assessment. 2014;1073191114533814.
18. Chatterjee A, Anderson K, Moskowitz C, Hauser W, KS M. A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2005;17(3): 378-83.
19. Rosenbaum D. Psychosis with Huntington's chorea. Psychiat Quart. 1941;15:93-9.
20. Tamir A, Whittier J, Korenyi C. Huntington's chorea: A sex difference in psychopathological symptoms. Dis Nerv Syst. 1969;30(2):103.
21. Dewhurst K, Oliver J, Trick K, McKnight A. Neuropsychiatric aspects of Huntington's disease. Confin Neurol. 1969;31(4):258-68.
22. Tyler A, Harper P, Davies K, Newcome R. Family Break-Down and Stress in Huntington's Chorea. J Biosoc Sci. 2008;15(02):127-38.
23. Burns A, Folstein S, Brandt J, Folstein M. Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis. 1990;178(1):20-6.
24. Pflanz S, Beeson J, Ebmeier K, Simpson S. The clinical manifestation of mental disorder in Huntington's disease: A retrospective case record study of disease progression. Acta Psychiatr Scandanavia. 1991;83:53-60.
25. Shiwach R, Patel V. Aggressive behaviour in Huntington's disease:Across-sectional study in a nursing home population. Behav Neurol. 1993;6:43-7.
26. Jensen P, Fenger K, Bolwig T, Sørensen S. Crime in Huntington's disease: A study of registered offences among patients, relatives and controls. J Neurol Neurosurg Psychiatry. 1998;65(4):467-71.
27. Craufurd D, Thompson J, Snowden J. Behavioral Changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-26.
28. Grimbergen Y, Knol M, Bloem B, Kremer B, Roos R, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord. 2008 May 15;23(7):970-6.
29. Anderson KE, Gehl CR, Marder KS, Begliner LJ, Paulsen, JS, Huntington's Study Group. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment Dis. 2010;198(5):334-8.
30. Thompson JC, Harris J, Sollom AC, Stopford CL, Howard E, Snowden JS, et al. Longitudinal Evaluation of Neuropsychiatric Symptoms in Huntington's Disease. J Neuropsychiatry Clin Neurosci. 2012;24(1):53-60.
31. Hubers A, van Duijn E, Roos R, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, et al. Suicidal ideation in a European Huntington's disease population. J Affect Disord. Elsevier; 2013;151(1):248-58.
32. Wetzel H, Gehl C, Dellefave-Castillo L, Schiffman J, Shannon K, Paulsen J. Suicidal ideation in Huntington disease: The role of comorbidity. Psychiatry Res. Elsevier Ltd; 2011;188(3):372-6.
33. Folstein M, Folstein S, McHugh P. Mini-mental state: A practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
34. Group HS. Unified Huntington's disease rating scale: Reliability and consistency. Mov Disord. 1996;11:136-42.
35. Patel V, Hope R. A rating scale for assessment of aggression in the elderly-the RAGE. Psychol Med. 1992;22(1): 211-21.
36. Wing J, Cooper J, Sartorius N. Measurement and classification of psychiatric symptoms. Cambridge: Cambridge Univeristy Press; 1974.
37. Leonard D, Kidson M, Brown J, Shannon P, Taryan S. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust NZ J Psychiat. 1975;9(2):115-8.
38. Stewart J. Adverse behavioral effects of amantadine therapy in Huntington's disease. South Med J. 1987;80(10):1324.
39. Stewart J. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. J Clin Psychiatry. 1987;48(3):106-8.
40. Stewart J, Mounts M, Clark R. Aggressive behavior in Huntington's disease: Treatment with propranolol. J Clin Psychiatry. 1987;48(3):106-8.
41. Von Hafften A, Jensen C. Paradoxical response to pindolol treatment for aggression in a patient with Huntington's disease. J Clin Psychiatry. 1989;50(6):203-31.
42. Findling R. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics. 1993;34(5):460-1.
43. Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry. 1994;151(7):1994.
44. Patel S, Tariot P, Asnis J. L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease. Ann Clin Psychiatry. 1996;8(1):23-6.
45. Ranen N, Lipsey J, Treisman G, Ross C. Sertraline in the Treatment of Severe Aggressiveness Huntington ' s Disease in. 1996;(3).
46. Bhandary A, Masand P. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics. 1997;38(4):389-91.
47. Grove V, Quintanilla J, DeVaney G. Improvement of Huntington's disease with olanzapine and valproate. New Engl J Med. 2000;343(13):973-4.
48. Blass D, Steinberg M, Leroi I, Lyketsos C. Successful Multimodal Treatment of Severe Behavioral Disturbance in a Patient With Advanced Huntington's Disease. Am J Psychiatry. 2001;158(12):1966-72.
49. Fogliani A, Giorgio A, Di Bonomo V. Awareness of involuntary movements in Huntington disease with olanzapine: A case report. Minerva Psychiatr. 2003;44(3):189-90.
50. Alpay M, Koroshetz WJ. Quetiapine in the Treatment of Behavioral Disturbances in Patients With Huntington's Disease. Psychosomatics. 2006;47(1):70-2.
51. Soliman S, Haque S, George E. Stalking and Huntington's Disease: A Neurobiological Link? J Forensic Sci. 2007;52(5):1202-4.
52. Edlinger M, Seppi K, FleischhackerW, Hofer A. Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. Int Clin Psychopharmacol. 2013;28(4):214-6.
53. Rej S, Desautels R. Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2013;25(3):E33-4.
54. Ding J, Gadit A. Psychosis with Huntington's disease: Role of antipsychotic medications. BMJ Case Rep. 2014;2014: 2013-5.
55. Brown A, Fisher C. Optimising Occupational Performance through Sensory Modulation: Case reports of two young adults diagnosed with Juvenile Huntington's Disease. Br J Occup Ther. In press.